EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access

Baseline Interleukin‐10 Levels as a Predictive Biomarker for Achieving Clinical Response With Abatacept in Patients Who Were Disease‐Modifying Antirheumatic Drug Naive and Anti–Citrullinated Protein Antibody Positive With Early Rheumatoid Arthritis

Jinqi Liu iD, Yicong Li, Kai Fu, Chun Wu, Peter Schafer, Sean E Connolly iD, Ian M Catlett, Michael A Maldonado, Robert Wong, Paul Emery iD, Yoshiya Tanaka iD, Vivian P Bykerk und 3 weitere

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.70106 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Jinqi Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Bristol-Myers Squibb, Princeton, New Jersey. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Abatacept, Interleukin-10, Antirheumatic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Bristol Myers Squibb, Bristol-Myers Squibb Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Predictive biomarkers for patients with early rheumatoid arthritis (RA) are needed. This exploratory post hoc analysis investigated inflammatory biomarkers associated with baseline disease activity and biomarkers predictive of treatment response in patients who were seropositive with early RA from a phase 3 study.

Methods

The AVERT‐2 study (NCT02504268) included patients who were disease‐modifying antirheumatic drug naive and anti–citrullinated protein antibody positive randomized to abatacept and methotrexate (MTX) or placebo and MTX for 56 weeks. Correlations were assessed among biomarkers and disease activity, pharmacodynamic (PD) changes on disease‐associated biomarkers in response to treatment, and baseline biomarkers to predict treatment response at week 52.

Results

In the analysis, 446 patients received abatacept and MTX and 300 received placebo and MTX. Of 103 biomarkers, 47 demonstrated a significant reduction in PD changes with abatacept and MTX versus placebo and MTX, with 18 out of 47 biomarkers showing correlations with baseline disease activity. High baseline interleukin‐10 (IL‐10) levels were associated with greater probability of achieving efficacy measures by week 52 in patients receiving abatacept and MTX versus placebo and MTX, consistent with a significant reduction in disease activity with abatacept and MTX ( P < 0.03 to P < 0.0007). Higher baseline IL‐10 levels were associated with lower bone erosive development with abatacept and MTX compared with placebo and MTX.

Conclusion

Treatment with abatacept and MTX resulted in significantly greater reduction of biomarkers relevant to RA, and high baseline IL‐10 levels predicted better treatment response with abatacept and MTX versus placebo and MTX across clinical outcomes. Findings suggest a well‐suited mechanism of action for abatacept and MTX in patients with early RA and high baseline IL‐10 levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAbataceptInterleukin-10Antirheumatic AgentsAnti-Citrullinated Protein AntibodiesHumansMethotrexateBiomarkersFemaleMiddle AgedMaleTreatment OutcomeDrug Therapy, CombinationAdult

Substanzen

AbataceptInterleukin-10Antirheumatic AgentsAnti-Citrullinated Protein AntibodiesMethotrexateBiomarkersIL10 protein, human

Autor:innen und Institutionen

  • Bristol-Myers Squibb, Princeton, New Jersey.
  • Parexel International, Durham, North Carolina.
  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom.
  • First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
  • Department of Rheumatology, Hospital for Special Surgery, New York, New York.
  • Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.

ORCID-Profile: Jinqi Liu, Sean E Connolly, Paul Emery, Yoshiya Tanaka, Clifton O Bingham, Roy Fleischmann

Förderung

  • Bristol Myers Squibb
  • Bristol-Myers Squibb Canada

Zitieren

APA

Liu, J., Li, Y., Fu, K., Wu, C., Schafer, P., Connolly, S. E., Catlett, I. M., Maldonado, M. A., Wong, R., Emery, P., Tanaka, Y., Bykerk, V. P., Bingham, C. O., Huizinga, T. W. J., & Fleischmann, R. (2026). Baseline Interleukin‐10 Levels as a Predictive Biomarker for Achieving Clinical Response With Abatacept in Patients Who Were Disease‐Modifying Antirheumatic Drug Naive and Anti–Citrullinated Protein Antibody Positive With Early Rheumatoid Arthritis. Arthritis & Rheumatology. https://doi.org/10.1002/art.70106

Vancouver

Liu J, Li Y, Fu K, Wu C, Schafer P, Connolly SE, et al. Baseline Interleukin‐10 Levels as a Predictive Biomarker for Achieving Clinical Response With Abatacept in Patients Who Were Disease‐Modifying Antirheumatic Drug Naive and Anti–Citrullinated Protein Antibody Positive With Early Rheumatoid Arthritis. Arthritis & Rheumatology. 2026. doi:10.1002/art.70106

BibTeX
@article{Liu2026,
  author = {Liu, Jinqi and Li, Yicong and Fu, Kai and Wu, Chun and Schafer, Peter and Connolly, Sean E and Catlett, Ian M and Maldonado, Michael A and Wong, Robert and Emery, Paul and Tanaka, Yoshiya and Bykerk, Vivian P and Bingham, Clifton O and Huizinga, Thomas W J and Fleischmann, Roy},
  title = {Baseline Interleukin‐10 Levels as a Predictive Biomarker for Achieving Clinical Response With Abatacept in Patients Who Were Disease‐Modifying Antirheumatic Drug Naive and Anti–Citrullinated Protein Antibody Positive With Early Rheumatoid Arthritis},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.70106}
}
Kostenlos starten →